The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
New Nanoparticle Strategies For Efficient Delivery And Controlled Release Into The Brain
Funder
National Health and Medical Research Council
Funding Amount
$571,633.00
Summary
A key challenge for treating neurodegenerative diseases is delivery of drugs across the blood–brain barrier (BBB). This project will develop advanced BBB “nanoshuttles” based upon systematic investigation of BBB penetration mechanisms and near-infrared drug controlled release strategy. These delivery systems may facilitate diagnosis of brain diseases and on-demand release of drug cargos to diseased cells in the brain, offering the potential of a brand new localised therapy for brain diseases.
Developing Insight Into The Molecular Origins Of Familial And Sporadic Frontotemporal Dementia And Amyotrophic Lateral Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$6,377,279.00
Summary
There is strong evidence that frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) represent a spectrum of neurodegenerative disease with common origins. A combined study of FTD/ALS patient cohorts will provide greater power to identify these shared molecular origins. We aim to discover gene variants that cause, predispose, or modify onset and progression of inherited and sporadic FTD/ALS, and validate and study our discoveries in new cell and animal models of these disorders.
Anti-inflammatory Copper Complexes For Treatment Of Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$603,622.00
Summary
Brain inflammation and disrupted metabolism of the biologically important metal, copper, play key roles in Alzheimer’s disease (AD) progression. Our team has developed new copper-based therapeutics, but limited knowledge of how they work impedes clinical trials. My recent findings indicate that these drugs potently prevent inflammation. My proposal seeks to understand how copper-complexes reduce damaging inflammatory responses in novel human cell models of AD.
Neuronal Membranes And Connections In Dementia: Targets For Intervention
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
This research aims to understand why some people with Mild Cognitive Impairment (MCI) progress to dementia, whilst others do not. The fact that some people’s cognitive abilities can improve provides an opportunity to study the mechanisms that protect their brain cells from the degeneration associated with dementia. Understanding the cellular changes will lead to therapies that can be tested in the lab for individuals.
Discovering Novel Molecules That Regulate Axonal Degeneration.
Funder
National Health and Medical Research Council
Funding Amount
$588,622.00
Summary
The axon is the primary signaling component of every neuron and is essential for normal function. Axonal degeneration is a key early pathological hallmark of Alzheimer’s disease. We lack a basic understanding of molecules that regulate this process. Such knowledge is essential for the development of treatments and therapies for dementia and the preservation of healthy ageing. I aim to discover the molecules that regulate axonal degeneration and study their function.